Merus NV (MRUS.OQ)
MRUS.OQ on NASDAQ Stock Exchange Global Market
17.49USD
20 Apr 2018
17.49USD
20 Apr 2018
Change (% chg)
$0.38 (+2.22%)
$0.38 (+2.22%)
Prev Close
$17.11
$17.11
Open
$16.99
$16.99
Day's High
$17.50
$17.50
Day's Low
$16.96
$16.96
Volume
5,934
5,934
Avg. Vol
10,316
10,316
52-wk High
$23.50
$23.50
52-wk Low
$13.33
$13.33
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Mark Iwicki |
50 | Chairman of the Supervisory Board | |
Ton Logtenberg |
Chief Executive Officer | ||
John Crowley |
41 | 2016 | Chief Financial Officer, Executive Vice President |
Shelley Margetson |
2016 | Chief Operating Officer, Executive Vice President | |
John de Kruif |
Chief Technology Officer |
- BRIEF-Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration
- BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement
- BRIEF-Merus Announces $55.8 Mln Private Placement Offering
- BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
- BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs